Moderna: new positive analysis for vaccine
(CercleFinance.com) - Moderna announces that the primary efficacy analysis of the phase III study of mRNA-1273, its investigational vaccine against Covid-19, conducted on 196 cases, confirms the efficacy observed in the first interim analysis at 94.
1%.
On this basis, the biotech company plans to file an emergency use authorization application with the US FDA and a conditional approval application with the European Medicines Agency.
In addition, on Sunday Moderna announced an amendment to the mRNA-1273 supply agreement with the UK government, increasing it by two million doses to seven million, starting in March 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
1%.
On this basis, the biotech company plans to file an emergency use authorization application with the US FDA and a conditional approval application with the European Medicines Agency.
In addition, on Sunday Moderna announced an amendment to the mRNA-1273 supply agreement with the UK government, increasing it by two million doses to seven million, starting in March 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.